Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+4.50%
-3.98%
+0.20%
-0.73%
+9.23%
MDWD
MediWound
$17.97
Login to display MediWound (MDWD) recommendation from the last 90 days from financial news and social media. Strengths
Earnings are forecast to grow
Chart
$16.57 (+8.45%)
$20.69 (-13.15%)
$17.52 (+2.57%)
$17.08 (+5.21%)
MDWD has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Low volume
MDWD overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Revenue increase YoY
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
MDWD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MDWD Street view is unimpressive and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayMDWD Earnings
The TTM reflects 12-month period, providing review of MDWD financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
What is MDWD current stock price?
What are MDWD stock strengths?
What risks are associated with MDWD stock?
When is MDWD next earnings report?
What is MDWD market cap and volume?
What is MDWD's current Stock IQ?
Should I buy MDWD stock right now?
Is MDWD a Strong Buy right now?
What does a 'Strong Buy' rating mean for MDWD?
What does a 'Strong Sell' rating mean for MDWD?
What factors influence MDWD's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.50%
-3.98%
+0.20%
-0.73%
+9.23%
MDWD
MediWound
Current Price
$17.97
Stock Insights
Strengths
Earnings are forecast to grow
Login to view MediWound (MDWD) recommendation from the last 90 days from financial news and social media.
Chart
$16.57 (+8.45%)
$20.69 (-13.15%)
$17.52 (+2.57%)
$17.08 (+5.21%)
MDWD Analysts Opinion
MDWD Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Revenue increase YoY
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
MDWD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MDWD Street view is unimpressive and have negative views on the near-term outlook
MDWD has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Low volume
Average key support and resistance price levels.
Login to displayMDWD Earnings
The TTM data reflects the most recent 12-month period, providing overview of MDWD financial performance.
MDWD Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
MDWD Latest Analysis
MediWound announces $30 million registered direct offering. shares down over 7%.
Today
MediWound raises $30 million in registered direct offering.
Today
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares.
Today
MediWound Says NexoBrid Granted Marketing Authorization For Burn Treatment In Australia . (RTTNews) - Israeli biotechnology company MediWound Ltd. (MDWD) announced that Australias Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid the Companys innovative enzymatic therapy for the removal of eschar in both adult and pediatric pat
Thu Sep 25, 2025
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia .
Thu Sep 25, 2025
Chronic Venous Insufficiency Market to Increase at a CAGR of 9.4% During the Forecast Period (2025–2034) Due to the Launch of Emerging Therapies and Chronic Venous Insufficiency Medical Devices | DelveInsight. Chronic Venous Insufficiency Market to Increase at a CAGR of 9.4% During the Forecast Period (2025–2034) Due to the Launch of Emerging Therapies and Chronic Venous Insufficiency Medical Devices |. DelveInsightThe total market size of chronic venous insufficiency in the leading geograph
Thu Sep 18, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MDWD Stock trends
MDWD Stock performance
MDWD Stock analysis
MDWD investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings